West Nile Virus Study (WNV)

Note that you will be prompted to log in or register an account

Accession Number

Study Type
Epidemiology Study

Collection Type
Open BioLINCC Study See bottom of this webpage for request information

Study Period
09/2009 – 08/2011

NHLBI Division

Clinical Trial URLs


Commercial Use Specimen Restrictions No

Non-Genetic Use Specimen Restrictions Based On Area Of Use No

Genetic Use Of Specimens Allowed? Yes

Genetic Use Area Of Research Restrictions No

Specific Consent Restrictions


The goal of the study was to enroll West Nile Virus (WNV) viremic donors into longitudinal natural history study, and characterize viral and immunological parameters.


WNV is the third most important mosquito-borne virus after malaria and dengue virus. Humans are infected by mosquito bites, blood transfusion and organ transplantation. While most infections are asymptomatic or mild, causing a self-limiting febrile illness, the young, old and immunocompromised individuals are at greater risk for severe, sometimes fatal disease. WNV first appeared in the US in 1999 raising concerns for blood supply safety. In the US epidemic of 2002 there were 23 cases of transfusion-transmitted infections (Pealer et al., NEJM 2003). The virus has spread rapidly across the US such that by the end of 2003 there were 19,000 documented cases of WNV infections in the US with 750 fatalities. Testing the blood supply was implemented in 2003. By 2013, 12 transfusion-associated WNV transmissions have been documented in the US.


A total of 63 WNV+ subjects, of which 54 WNV+ had symptom questionnaires and longitudinal samples collected for characterization and inclusion in the database and repository. Approximately half the subjects developed symptomatic disease based on the study criteria.


The subjects were identified when they presented themselves for blood donation and tested positive for WNV by nucleic acid testing (NAT). They were then contacted and enrolled in the study. On or around week 2 post blood donation, the subjects completed symptom questionnaires and provided a blood sample. Blood samples were also collected on weeks 3, 4, 6, 8, 12, and at 6, 9 and 12 months following the donation of the initial WNV+ blood donation that tested. Immunologic and viral studies were performed on the blood samples and aliquots were stored in the sample repository.

Additional Details

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3 of the BioLINCC handbook describes the components of the review process

Visits (Vials):


 PlasmaPacked CellsWhole BloodPBMCTotal
Week 151842365181114
Week 261352365231224
Week 355952365591206
Week 459644375651242
Week 653050376121229
Month 254848345541184
Month 348233305531098
Month 643956345351064
Month 946379324491023
Month 1243773304891029


Visits (Subjects):


Total number of subjectsAverage volume (ml) per subject
Week 15417.11
Week 25420.20
Week 35318.85
Week 45320.06
Week 65317.82
Month 24919.06
Month 34519.08
Month 64716.64
Month 94717.63
Month 124616.89


 Whole Blood
Total number of subjectsAverage volume (ml) per subject
Week 1367.83
Week 2367.81
Week 3367.78
Week 4377.84
Week 6377.81
Month 2347.79
Month 3307.87
Month 6347.88
Month 9327.63
Month 12307.67


 Packed Cells
Total number of subjectsAverage vials per subject
Week 1421.00
Week 2521.00
Week 3521.00
Week 4441.00
Week 6501.00
Month 2481.00
Month 3331.00
Month 6411.37
Month 9471.68
Month 12431.70


Total number of subjectsAverage vials per subject
Week 1549.59
Week 2549.69
Week 35310.55
Week 45310.66
Week 65311.55
Month 24911.31
Month 34512.29
Month 64711.38
Month 9479.55
Month 124610.63

Please note that researchers must be registered on this site to submit a request, and you will be prompted to log in. If you are not registered on this site, you can do so via the Request button. Registration is quick, easy and free.

Resources Available

Specimens Only

Materials Available

  • Packed Cells
  • Peripheral Blood Mononuclear Cells
  • Plasma
  • Whole Blood
  • More Details

Study Documents

Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message. If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.